Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2026)

Ginkgo Bioworks Holdings' EBITDA history runs 7 years deep, the most recent figure standing at -$71.4 million for Q1 2026.

• Quarterly EBITDA rose 11.85% year-over-year to -$71.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297.7 million (up 35.67% YoY) and the FY2025 annual result came in at -$315.3 million, up 43.68% from the prior year.
• EBITDA was -$71.4 million for Q1 2026 at Ginkgo Bioworks Holdings, down from -$70.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$55.2 million in Q3 2024 and bottomed at -$675.4 million in Q1 2022.
• A 5-year average of -$236.0 million and a median of -$178.1 million in 2023 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 86.3% in 2022, while the deepest fall reached 2355.53% in 2022.
• Ginkgo Bioworks Holdings' EBITDA stood at -$230.9 million in 2022, then gained by 22.85% to -$178.1 million in 2023, then surged by 41.83% to -$103.6 million in 2024, then surged by 31.71% to -$70.8 million in 2025, then declined by 0.88% to -$71.4 million in 2026.
• Business Quant data shows DNA's EBITDA at -$71.4 million in Q1 2026, -$70.8 million in Q4 2025, and -$90.0 million in Q3 2025.